Effects of SDZ NVI-085, a putative subtype-selective α1-agonist, on canine cataplexy, a disorder of rapid eye movement sleep

Abstract

Canine narcolepsy is an animal model of the human rapid eye movement sleep disorder. Dogs exhibit bouts of sleep attacks and muscle atonia (cataplexy) that are induced by emotions and thought to be abnormal rapid eye movement sleep episodes. We have previously demonstrated that cataplexy is strongly inhibited by increases in noradrenergic activity. This effect is mediated through central α 1-adrenoceptors, presumably of the α 1B subtype. In this study, we demonstrate with the canine model that SDZ NVI-085, a new compound with alerting effects, is a potent anticataplectic agent that may act through stimulation of an α 1-adrenoceptor subtype.